Replies to post #346544 on Amarin Corp Plc (AMRN)

[Laurent Maldague]

I'm guessing selling to a Euro BP is the gameplan. In terms of timing,
I think nothing happens until after European patents for vazkepa (extending exclusivity to 2039) are granted, Prepare IT/MITIGATE and BRAVE results are released. However, it should be critical to sell very soon after these events. There is potentially enormous value in finishing full scale Alzheimer's/colon cancer/NASH ect. trials PRIOR to European regulatory/patent exclusivity expiring. Amarin can't afford to wait too long for these add-on indications: ideally results start rolling out 2027-ish and the 2030-2039 period is where the biggest revenues should be reaped. I don't think Amarin has the money to both launch in Europe and get these large trials started ASAP. The obvious solution should be a BP buyout sometime next year.